Quantum BioPharma Ltd(QNTM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 21 at 7:57 PM ET (Korea 10/22 08:57)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -5.69 | Insider Own | 13.05% | Shs Outstand | 7.6M | Perf Week | -9.77% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 7.0M | Perf Month | -35.14% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 7.56% | Short Float | 5.14% | Perf Quarter | -15.49% |
| Income | -0.03B | P/S | - | EPS this Y | - | Inst Trans | 4.9% | Short Ratio | 1.74 | Perf Half Y | -28.36% |
| Sales | 0.00B | P/B | 2.29 | EPS next 5Y | - | ROA | -169.48% | Short Interest | 0.36M | Perf YTD | -67.12% |
| Book/sh | 1.05 | P/C | 1.99 | EPS past 3/5Y | -135.55% -24.71% | ROE | -429.58% | 52W High | -83.99% ($14.99) | Perf Year | -83.64% |
| Cash/sh | 1.21 | P/FCF | - | Sales past 3/5Y | - | ROIC | -316.49% | 52W Low | 15.94% ($2.07) | Perf 3Y | -96.67% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 56.35% | Gross Margin | - | Volatility(W/M) | 6.77% 7.66% | Perf 5Y | -97.52% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.23 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.19 | EPS Q/Q | 84.03% | Profit Margin | - | RSI (14) | 28.66 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.2 | Sales Q/Q | - | SMA20 | -23.13% ($3.12) | Beta | 0.45 | Target Price | $8 |
| Payout | - | Debt/Eq | 0.12 | Earnings | 2026/8/13 | SMA50 | -26.89% ($3.28) | Rel Volume | 0.44 | Prev Close | $2.43 |
| Employees | 7 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -40.75% ($4.05) | Avg Volume(3M) | 0.21M | Price | $2.4 |
| IPO | 2018/6/8 | Option/Short | No/Yes | Trades | 343 | Volume | 90,623 | Change | -1.23% |
🧠 This Canadian biotech researches a wide range of therapeutics for neurodegenerative, inflammatory, and metabolic diseases — including multiple sclerosis (MS) and alcohol use disorder. Its lead pipeline candidate, Lucid-MS, is a novel-mechanism compound that inhibits myelin damage and is preparing for a Phase 2 clinical trial. The company also runs a strategic investment arm, making it a micro-cap biotech.
Over the past 1 year, on the lower side
84% below its 1-year high.
Traded less than usual. That is 44% of its average volume.
QNTM has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.5%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 7.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
PSIL AdvisorShares Psychedelics ETF - It ranks #467 of 595 in the industry
Based on market cap of $19M.
BYSI#466 BeyondSpring Inc $20M PER - QNTM#467 Quantum BioPharma Ltd $19M PER - 
MRKR#468 Marker Therapeutics Inc $19M PER - 
NEUP#469 Neuphoria Therapeutics Inc $19M PER - 
COCP#470 Cocrystal Pharma Inc $18M PER - 
FAQ
What kind of company is QNTM?
QNTM belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of QNTM?
The market cap of QNTM is approximately $19M, ranking 5,233 within its sector.
What is the 52-week high and low for QNTM?
QNTM has recorded a 52-week high of $14.99 and a low of $2.07.
